Condensed Consolidated Statements Of Operations | |
Related party revenue | |
Technology and license revenue | 0 |
Grant revenue | |
Total revenues | |
Operating expenses: | |
Research and development | 2K |
General and administrative | 2.99M |
Restructuring charge | |
Total operating expenses | 2.99M |
Loss from operations | -2.99M |
Interest income and other income, net | -243K |
Loss from continuing operations before income taxes | -3.2M |
Income tax benefit for continuing operations | 0 |
Loss from continuing operations | |
Discontinued Operations: | |
Income (loss) from discontinued operations | |
Gain on sale of discontinued operations | |
Income tax expense for discontinued operations | |
Income from discontinued operations | |
Net income (loss) | -3.2M |
Net income (loss) attributable to non-controlling interests | 0 |
Net income (loss) attributable to Maxygen, Inc. | -3.2M |
Basic and diluted net income (loss) per share: | |
Continuing operations | |
Discontinued operations | |
Attributable to Maxygen, Inc. | |
Shares used in basic and diluted net income (loss) per share calculations |